


IQVIA joins FDA to advance COVID-19 understanding through CARE project

13 October 2020 | News

The CARE Project is open to US-based residents who think they may have been exposed to the coronavirus



US-based IQVIA in scientific partnership with the US Food and Drug Administration (FDA), will provide agile analytics from IQVIA's CARE Project COVID-19 registry to support a better understanding of how people in the community are affected by exposure to the coronavirus. IQVIA's research will show what symptoms individuals experience, the length and severity and whether any medications or vitamin supplements they are taking affect the severity of their coronavirus symptoms.

The CARE Project is open to US-based residents who think they may have been exposed to the coronavirus, regardless of whether they have been diagnosed with COVID-19, including people who have continued with everyday life and may have been exposed. The project was established to advance understanding of COVID-19 as experienced in community settings.

The registry was launched in April 2020. More than 20,000 people have enrolled so far, representing all 50 states and Washington, DC. Powered by the IQVIA CORE™, IQVIA leverages its healthcare expertise, data, analytics and technology to help clients integrate human science expertise with advances in data science and technology to make better decisions that will advance human health.